Candriam S.C.A. Achilles Therapeutics PLC Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding ACHL
# of Institutions
25Shares Held
24.4MCall Options Held
0Put Options Held
0-
Syncona Portfolio LTD Guernsey, Channel Islands, X011.1MShares$11.6 Million14.01% of portfolio
-
Bml Capital Management, LLC Zionsville, IN4.1MShares$4.31 Million2.46% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.39MShares$2.51 Million0.42% of portfolio
-
Redmile Group, LLC San Francisco, CA1.61MShares$1.69 Million0.11% of portfolio
-
Vestal Point Capital, LP New York, NY1.5MShares$1.58 Million0.12% of portfolio
About Achilles Therapeutics plc
- Ticker ACHL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,774,000
- Market Cap $42.8M
- Description
- Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...